Allergan Reports Results of Rapastinel in Four P-III RAP-MD Studies for Major Depressive Disorders (MDD)

Shots:

• The P-III RAP-MD (01,02,03,04) studies involve assessing of Rapastinel (450mg, 225mg) vs PBO as an adjunctive treatment of MDD
• The P-III RAP-MD-04 study demonstrated unmet 1EPs & 2EPs. RAP-MD (01,02,03) studies resulted that Rapastinel was well tolerated with no psychotomimetic side effects
• Rapastinel (IV, qw) is a novel anti-depressant, enhanced NMDAR activity by acting as a partial agonist at the glycine site

Click here to read full press release/ article | Ref: Allergen | Image: Endpoints News